The viral UL97 protein kinase, which is necessary for CMV replication, is the target of maribavir’s activity. maribavir stops the virus from reproducing by impeding this enzyme, hence reducing the infection’s ability to propagate
maribavir’s therapeutic range is mainly dedicated to the management of CMV infections. For the treatment of CMV infections in transplant recipients who are resistant or refractory to conventional antiviral treatments, it has received FDA approval. maribavir has been demonstrated in clinical studies to be efficient in lowering the viral load and avoiding the recurrence of CMV infections.